At this moment, several independent studies have described active site or allosteric MALT1 protease inhibitors (11–14, 40–45), and mouse studies have already indicated the therapeutic value of some of these inhibitors in certain types of cancer (13, 14, 43, 46) and inflammatory diseases (40). The gene discussed is MALT1; the disease is cancer.